Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Direct-to-Consumer Off-Label Drug Promotion Survey Results

3,548 views

Published on

Results from two surveys: (1) an online survey hosted by Pharma Marketing News and primarily focused on pharma executive participants and (2) an inVibe voice-response survey of patients, patient advocates, and caregivers sponsored by Pharma Marketing News. Preliminary results from these surveys were presented at an FDA public hearing on 9 November 2016.

Published in: Health & Medicine
  • Be the first to comment

Direct-to-Consumer Off-Label Drug Promotion Survey Results

  1. 1. P R E S E N TAT I O N M A D E AT F D A P U B L I C H E A R I N G , W E D N E S D AY, 9 N OV E M B E R 2 0 1 6 ( U P D AT E D V E RS I O N )
  2. 2. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey FDA NOTICE HINTS AT OFF-LABEL DTC COMMUNICATIONS BY PHARMA “To what extent is it appropriate for firms to communicate information about unapproved uses of their approved/cleared medical products to patient and consumer audiences?” “What disclosures and additional information would be needed to help ensure that a communication to lay audiences is truthful and non-misleading, given consumers’ lack of medical training and expertise in critically evaluating this type of information?”
  3. 3. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey PMN SURVEY* RESPONDENT PROFILE Affiliation N = 30 77% are very or somewhat supportive of drug industry 63% are U.S. based *Online survey hosted by Pharma Marketing News Access up-to-date results here: http://bit.ly/offlabelDTCsurveyResults
  4. 4. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey SUMMARY OF RESULTS: GUIDELINES? FDA should create non-legally binding GUIDELINES for off- label DTC promotions by pharma companies.
  5. 5. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey SUMMARY OF RESULTS: REGULATIONS? FDA should create legally binding REGULATIONS for off- label DTC promotions by pharma companies.
  6. 6. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey SUMMARY OF RESULTS: NEITHER! Under NO circumstances should FDA allow off- label drug promotion to patients or consumers.
  7. 7. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey SUMMARY OF RESULTS: THINK TANK INPUT A Duke University think tank suggested that a new independent entity be created to review claims and recommend exactly what off-label information drug and device makers should be allowed to share with doctors. Should such an independent entity do the same with regard to off-label information shared with consumers?
  8. 8. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey SELECTED COMMENTS “I work in communications for biotech and pharma companies, and I think that regardless of regulation, we have an ethical obligation to be cautious in how we communicate directly to consumers about drugs and medical devices, both for the sake of patient safety, but also for healthcare economic reasons. Our industry, which deals with situations where lives are hanging in the balance, would do well to always pause and ask itself if what it does is ethical.” – Employed at ad agency; Very supportive of drug industry “Marketing of off-label drugs would be easy to abuse, and would become a disincentive to do well controlled and sufficiently powered studies needed to protect the public.” – Consumer, consumer advocate, patient, or other non-industry aligned member of the public; Very supportive of drug industry
  9. 9. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey ONE MORE COMMENT “There's enough confusion with and panning of current legal DTC. There is just too much information being shared with each TV ad. There appears to be a strong, growing movement from medical professionals to ban DTC. Adding an off-label element is 100% unnecessary. If anything, laws should change that only allow the brand name, generic, and indication to be shared with consumers and direct to the product website. If consumers are really doing their own (online) homework and relying on their research to help understand their or their loved ones condition, then FDA should foster that by creating better DTC--less information sharing on TV. Force consumers to go to the product website and learn more. Let the consumer absorb the info at their own pace.” ” – Legal/regulatory professional; Very supportive of drug industry
  10. 10. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey INVIBE SURVEY* RESPONDENT PROFILE N = 51 40 Patient Advocates 20 Chronic Condition Patients 9 Caregivers 100% are U.S. based *Voice-response survey sponsored by Pharma Marketing News Conditions: • Diabetes (8) • Fibromyalgia (7) • Arthritis (5) • CHF (5) • Back Pain (4) • Migraine (4) • Asthma (3) • Crohn’s Disease (3) • Hypertension (3) • Rheumatoid Arthritis (3) • Sjogren’s Syndrome (3) • Other (12)
  11. 11. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey SUMMARY OF RESULTS Do you think the FDA should allow off-label promotion of drugs to consumers by drug companies as long as the promotions (magazine and TV ads) provide truthful information based on current science.
  12. 12. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey SELECTED COMMENTS FROM PATIENTS Comments against:Comments in favor: Click icons above to hear comments or go here: http://bit.ly/OffLabelPatientSurvey
  13. 13. 2016. Pharma Marketing Network. All rights reserved. Off-Label DTC Survey THANKS FOR VIEWING!

×